透析患者におけるアシクロビル代謝物ＣＭＭＧのアシクロビル脳症への関与
スポンサーリンク
概要
- 論文の詳細を見る
The administration of acyclovir (ACV) sometimes causes neurotoxicity in patients with renal failure and recent research suggests that it is caused by 9-carboxymethoxymethylguanine (CMMG),the main metabolite of ACV,rather than ACV itself.In this study,therefore,we determined whether such neurotoxicity in dialysis patients was associated with serum levels of ACV or CMMG.Between December 2000 and August 2006,we obtained serum samples from dialysis patients who had been treated with ACV for herpes zoster infections,and who had adequate data for assessment.The patients were divided into two groups : with neurotoxicity (Group A) and without neurotoxicity (Group B).Serum concentrations of ACV and CMMG were measured by HPLC and compared between the 2 groups.CMMG/ACV ratios were also compared.There were 9 subjects in Group A and 18 in Group B and subject backgrounds were similar.ACV serum concentrations were not significantly different between the two groups-median (range) 6.6 (1.1-9.9)μg/mL and 3.6 (0.5-12.1)μg/mL respectively (P =0.26).However,serum CMMG concentrations were significantly higher in Group A than in Group B-median (range) 10.4 (6.6-17.2)μg/mL and 2.4 (0.0-11.8)μg/mL respectively (P <0.001).The serum CMMG/ACV ratio was also higher in Group A than in Group B-median (range) 2.17 (0.75-10.20)and 0.64 (0.00-3.citation=16)respectively (P <0.01).These results suggest that the development of neurotoxicity is associated with the accumulation of CMMG in the serum.The monitoring of serum CMMG concentrations could be therefore be useful for predicting neurotoxicity during ACV treatment in patients with renal failure.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)